Tomas J. Philipson, PhD

Vaccination of children born in the United States in 2009 will save 1.2 million quality-adjusted life-years, generating $184 billion in social value net of vaccination costs.

Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non—HCV-mediated liver failure.

Instrumental variables regression analysis indicated that inpatient oral nutritional supplement use decreased length of stay, episode cost, and 30-day readmission probability.

This article studies the association of pharmacy cost sharing with antiplatelet therapy utilization and health outcomes for patients with acute coronary syndrome.